Insmed Incorporated (INSM) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

on your telephone keypad. If you'd like to withdraw your question, again, press the star and one. Please limit to one question. I would now like to turn the call over to Brian Dunn, Head of Investor Relations. You may begin. Thank you, Kayla. Good day, everyone, and welcome to today's conference call to discuss Inns Med's third quarter 2025 financial results and provide an update on our business. Before we start, please note that today's call will include forward-looking statements. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the projections discussed. Please refer to our filings with the Securities and Exchange Commission for more information. Also note that our call today will include blinded observations from our ongoing Phase II study of Brents of Kadib and CRS without nasal polyps. These observations may not be representative of results once the study is completed and all data is collected and analyzed. As a result, any future interim data readouts and the final data from this study may be materially different than the observations described today. The information we will discuss on today's call is meant for the benefit of the investment community. It is not intended for promotional purposes, and it is not sufficient for prescribing decisions. Today's call will feature prepared comments by Will Lewis, Chair and Chief Executive Officer, Roger Adset, Chief Operating Officer, and Sarah Bonstein, Chief Financial Officer. After their comments, they will be joined by Martina Flammer, Chief Medical Officer, for the Q&A session. I will now turn the call over to Will. Thank you, Brian. I am enormously pleased to welcome all of you to InnsMed's first earnings cal...